CBD Oil: The New Alternative for Chronic Pain?

Using CBD Oil for Pain Relief

CBD oil is quickly becoming a mainstream product for chronic pain, stress, anxiety, and other ailments. The cannabis-derived chemical contains safe and natural medicinal benefits without the side effects of NSAIDs, analgesics, or opioids. In fact, many patients who previously relied on Tylenol, Ibuprofen, or Vicodin to control pain found CBD to help cut down on the number of pills needed to function each day. CBD oil is worth a try for anyone looking to relieve chronic pain.

Cannabidiol (CBD Oil ) oil is used by some people with chronic pain. CBD oil may reduce pain, inflammation, and overall discomfort related to a variety of health conditions. CBD oil is a product made from cannabis. … But there needs to be more research in order to verify the pain-relieving benefits of CBD oil. Researchers think that CBD interacts with receptors in your … This means that CBD oil may benefit people with chronic pain

Symptoms of Chronic Pain

Simply put, chronic pain is just pain that never really goes away. Sometimes it’s associated with a larger problem such as arthritis, fibromyalgia, or multiple sclerosis. It can come on in any form of pain sensation whether it be dull, aching, pins and needles, or sensitivity. Nerve dysfunction and inflammation are two causes of chronic pain, which can be genetic or brought on diet and lifestyle habits. In 2015, about 25 million adults were reported as having some form of chronic pain.

The opioid crisis in the US has been peaking every year since the year 2000, and measures have been taken in order to calm down the pill-fueled storm but nothing seems to catch on as long as doctors keep prescribing opioids as a primary way of pain management. The Number of opioid pain relievers prescribed in the United States jumped significantly from 76 million in 1991 to 207 million in 2013.

Opioids and anti-inflammatory drugs like NSAIDs are the most common approach to dealing with daily occurrences. But what few realize is that even these everyday drugs come with a laundry list of side effects, including death.

In fact, if NSAID deaths were calculated separately in National Vital Statistics reports, they would be the 15th leading cause of death in the US. 

One of the biggest benefits of CBD oil is the potential to reduce the number of pills needed for relief. Most of us can handle Tylenol, Advil, or opioids in moderation. However, these drugs can still lead to gastrointestinal damage, increased tolerance, dependency, addiction, and overdose.

People tend to use prescription or over-the-counter drugs to relieve stiffness and pain, including chronic pain.

Some people believe that CBD offers a more natural alternative without the risk of addition.

Authors of a study published in the Journal of Experimental Medicine found that CBD significantly reduced chronic inflammation and pain in some mice and rats.

Which Conditions Can CBD Help?

The researchers suggested that the non-psychoactive compounds in marijuana, such as CBD, could constitute a new treatment for chronic pain. The potential benefits of CBD oil includes Arthritis pain, Multiple sclerosis, Chronic pain and Fibromyalgia.

CBD is also recommended for patients with Crohn’s disease, a chronic condition caused by inflammation of digestive lining. Like MS, Crohn’s has no cure and CBD is recommended to calm pain during flare-ups.

Cannabinoid has shown positive results when put up against many chronic illnesses, particularly those throughout the immune or nervous system.

CBD oil is also highly recommended for patients with fibromyalgia, arthritis, and undiagnosed chronic pain.

CBD Oil is one of the biggest factors in the fight against opioids, especially in states which have already legalized medical cannabis. In fact, CBD oil has proven to be a very effective way of managing pain and the side effects of chemotherapy and similar cancer treatments.

These oils have been known to completely replace opioids as a primary way of relieving chronic pain, but that’s not the only thing as it is impossible to overdose on these oils.

Meanwhile, opioid overdoses are happening every day across the states.

And it’s not like these oils are not easily available.

95% of the US population lives within states that have some kind of cannabis law that permits CBD oils. CBD oil does not cause gastrointestinal damage and it is not known to be habit-forming. All it takes for a patient to become addicted to opioids is a 10-day prescription, which can be prescribed for anything from a pulled muscle to a kidney stone.

SOURCES

    1. About the Epidemic. (n.d.). U.S. Department of Health & Human Services. Retrieved fromhttps://www.hhs.gov/opioids/about-the-epidemic/.
    1. Abrams, D.I., Couey, P., Shade, S.B., Kelly, M.E., and Benowitz, N.L. (2011, December). Cannabinoid–Opioid Interaction in Chronic Pain. Clinical Pharmacology & Therapeutics, 90(6), 844-51. Retrieved from http://onlinelibrary.wiley.com/wol1/doi/10.1038/clpt.2011.188/full.
    1. Borgelt, L.M., Franson, K.L., Nussbaum, A.M., Wang, G.S. (2013, February). The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy, 33(2), 195-209. Retrieved fromhttp://onlinelibrary.wiley.com/wol1/doi/10.1002/phar.1187/full.
    1. Bosshard, S.C., Grandjean, J., Schroeter, A., Baltes, C., Zeilhofer, H.U., and Rudin, M. (2012, July). Hyperalgesia by low doses of the local anesthetic lidocaine involves cannabinoid signaling: An fMRI study in mice. Pain, 153(7), 1450-8. Retrieved fromhttp://journals.lww.com/pain/pages/articleviewer.aspx?year=2012&issue=07000&article=00019&type=abstract.
    1. Burston, J.J., Sager, D.R., Shao, P., Bai, M., King, E., Brailsford, L., Turner, J.M., Hathway, G.J., Bennett, A.J., Walsh, D.A., Kendall, D.A., Lichtman, A., and Chapman, V. (2013, November 25). Cannabinoid CB2 Receptors Regulate Central Sensitization and Pain Responses Associated with Osteoarthritis of the Knee Joint. PLOS One, 8(11), e80440. Retrieved fromhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840025/.
    1. Carlini, B.H., Garrett, S.B., and Carter, G.T. (2015, September). Medicinal Cannabis: A Survey Among Health Care Providers in Washington State. The American Journal of Hospice & Palliative Care. Retrieved fromhttp://journals.sagepub.com/doi/pdf/10.1177/1049909115604669.
    1. Cottler, L. B., Abdallah, A. B., Cummings, S. M., Barr, J., Banks, R., & Forchheimer, R. (2011). Injury, Pain, and Prescription Opioid Use Among Former National Football League (NFL) Players. Drug and Alcohol Dependence, 116(1-3), 188–194. Retrieved fromhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095672/.
    1. Cravatt, B.F., and Lichtman, A.H. (2004, October). The endogenous cannabinoid system and its role in nociceptive behavior. Journal of Neurobiology, 61(1), 149-60. Retrieved fromhttp://onlinelibrary.wiley.com/doi/10.1002/neu.20080/epdf.
    1. Emerich, B.L., Ferreira, R.C.M., Cordeiro, M.N., Borges, M.H., Pimenta, A.M.C., Figueiredo, S.G., Duarte, I.D.G., and de Lima, M.E. (2016). δ-Ctenitoxin-Pn1a, a Peptide from Phoneutria nigriventer Spider Venom, Shows Antinociceptive Effect Involving Opioid and Cannabinoid Systems, in Rats. Toxins, 8(4), 106. Retrieved fromhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848632/.
    1. Fine, P.G., and Rosenfeld, M.J. (2014). Cannabinoids for Neuropathic Pain. Current Pain and Headache Reports, 18(10), 451. Retrieved fromhttp://link.springer.com/article/10.1007%2Fs11916-014-0451-2.
    1. Gerak, L.R., and France, C.P. (2016, May). Combined treatment with morphine and Δ9-tetrahydrocannibinol (THC) in rhesus monkeys: antinociceptive tolerance and withdrawal. The Journal of Pharmacology and Experimental Therapeutics, 357(2), 357-66. Retrieved fromhttp://jpet.aspetjournals.org/content/357/2/357.long.
    1. Hirsh, A.T., Kratz, A.L., Engel, J.M., and Jensen, M.P. (2011). Survey Results of Pain Treatments in Adults with Cerebral Palsy. American Journal of Physical Medicine & Rehabilitation / Association of Academic Physiatrists, 90(3), 207–216. Retrieved fromhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036542/.
    1. Kinsey, S.G., Mahadevan, A., Zhao, B., Sun, H., Naidu, P. S., Razdan, R.K., Selley, D.E., Damaj, M.I., and Lichtman, A.H. (2011). The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. Neuropharmacology, 60(2-3), 244–251. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021987/.
    1. Lee, M.C., Ploner, M., Wiech, K., Bingel, Ul, Wanigasekera, V., Brooks, J., Menon, D.K., and Tracey, I. (2013, January). Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain, 154(1), 124-134. Retrieved fromhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549497/.
    1. Li, M.H., Suchland, K.L., and Ingram, S. (2016, December). Compensatory activation of cannabinoid CB2 receptor inhibition of GABA release in the rostral ventromedial medulla (RVM) in inflammatory pain. Journal of Neuroscience, 1310-16. Retrieved fromhttp://www.jneurosci.org/content/early/2016/12/09/JNEUROSCI.1310-16.2016.1.
    1. Pain: Hope Through Research (2015, September 4). National Institute of Neurological Disorders and Stroke. Retrieved from https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Pain-Hope-Through-Research.
    1. Perron, B.E., Bohnert, K., Perone, A.K., Bonn-Miller, M.O., & Ilgen, M. (2015). Use of Prescription Pain Medications Among Medical Cannabis Patients: Comparisons of Pain Levels, Functioning, and Patterns of Alcohol and Other Drug Use. Journal of Studies on Alcohol and Drugs, 76(3), 406–413. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440298/.
    1. Roberts, J.D., Gennings, C., and Shih, M. (2006, January). Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. European Journal of Pharmacology, 530(1-2), 54-8. Retrieved fromhttp://www.sciencedirect.com/science/article/pii/S001429990501215X.
    1. Russo, E.B., and Hohmann, A.G. (2012, September 22). Role of cannabinoids in pain management. Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches, 181-197. Retrieved fromhttp://link.springer.com/chapter/10.1007%2F978-1-4614-1560-2_18.
    1. Staahl, C., Olesen, A.E., Andresen, T., Arendt-Nielsen, L., and Drewes, A.M. (2009, September). Assessing efficacy of non-opioid analgesics in experimental pain models in healthy volunteers- an updated review. British Pharmacological Society, 68(3), 322-341. Retrieved fromhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2766472/.
    1. Wakley, A.A., Wiley, J.L., and Craft, RM. (2014). Sex differences in antinociceptive tolerance to delta-9-tetrahydrocannabinol in the rat. Drug and Alcohol Dependence, 143, 22–28. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161674/.
    1. Ware, M.A., Doyle, C.R., Woods, R., Lynch, M.E., and Clark, A.J. (2003, March). Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain, 102(1-2). Retrieved fromhttp://journals.lww.com/pain/Abstract/2003/03000/Cannabis_use_for_chronic_non_cancer_pain__results.23.aspx.
    1. Ware, M.A., Wang, T., Shapiro, S., and Collet, J.P. (2015, September 15). Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). The Journal of Pain. Retrieved from http://www.jpain.org/article/S1526-5900(15)00837-8/fulltext.
    1. Webb, C. W., & Webb, S. M. (2014). Therapeutic Benefits of Cannabis: A Patient Survey. Hawai’i Journal of Medicine & Public Health, 73(4), 109–111. Retrieved fromhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998228/.
    1. Wilsey, B., Marcotte, T. D., Deutsch, R., Gouaux, B., Sakai, S., & Donaghe, H. (2013). Low Dose Vaporized Cannabis Significantly Improves Neuropathic Pain. The Journal of Pain : Official Journal of the American Pain Society, 14(2), 136–148. Retrieved fromhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566631/.
    1. Wilsey, B., Marcotte, T.D., Deutsch, R., Zhao, H., Prasad, H., and Phan, A. (2016) An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain from Spinal Cord Injury and Disease. Journal of Pain, doi: 10.1016/j.pain.2016.05.010. Retrieved from http://www.jpain.org/article/S1526-5900(16)30072-4/fulltext.
  1. Woodhams, S.G., Sagar, D.R., Burston, J.J., and Chapman, V. (2015). The role of the endocannabinoid system in pain. Handbook of Experimental Pharmacology, 227, 119-43. Retrieved from http://link.springer.com/chapter/10.1007%2F978-3-662-46450-2_7.
Disclaimer : This website contains general information about cbd oil and the possible health benefits. The information is not advice and is not a substitute for advice from a healthcare professional. You must not rely on the information  as an alternative to medical advice from your doctor or other professional healthcare providers. FDA Disclosure:CBD products are not approved by the FDA for the diagnosis, cure, mitigation, treatment, or prevention of any disease. While we publish and refer to currently available research on cannabidiol, terpenoids and other properties of hemp-derived cannabis oils, it is important to note: None of the products or information available on this website are intended to be a treatment protocol for any disease state. The information presented is for educational purposes only and should not be construed as medical advice or instruction.  The FDA would want us to remind you: You should always seek the advice of a physician before adding any supplements to your diet.

Leave a Reply

Your email address will not be published. Required fields are marked *